parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.08 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in late spermatids	0.75
chemistry Open Targets	compounds already reach it: verubecestat, atabecestat, lanabecestat +1	0.90
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	81 Parkinson's papers of 4,263	0.42
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 3199

receipt 3207: BACE1 in dopamine neurons, braak

power: full sample -0.09 (p 0.735, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.11 (p 0.658, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.603, n 18). could be the mix.
skeptic: leave-one-out range -0.24 to +0.05, sign flips 3; without severely affected donors -0.09 (p 0.735, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BACE1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3206: BACE1 in oligodendrocytes, braak

power: full sample -0.26 (p 0.306, n 18), 95% CI -0.65 to +0.24. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.27 (p 0.277, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.30 (p 0.228, n 18). could be the mix.
skeptic: leave-one-out range -0.44 to -0.16, sign flips 0; without severely affected donors -0.26 (p 0.306, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BACE1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts